Relay Therapeutics beats Q4 revenue expectations

Reuters02-27
<a href="https://laohu8.com/S/RLAY">Relay Therapeutics</a> beats Q4 revenue expectations

Overview

  • Clinical-stage precision medicine firm's Q4 revenue beat analyst expectations

  • Net loss for Q4 came in narrower than analysts' expectations

  • Company ended 2025 with $555 mln in cash, funding expected into 2029

Outlook

  • Relay Therapeutics expects initial Phase 1 data for vascular anomalies in 1H 2026

  • Company plans to present Phase 1/2 breast cancer data at ESMO TAT in March 2026

  • Relay Therapeutics to announce breast cancer triplet data and Phase 3 plans in 2026

Result Drivers

  • REVENUE INCREASE - Revenue rose due to licensing agreement with Elevar Therapeutics, contributing to a beat on analyst expectations

  • R&D EXPENSES - R&D expenses decreased due to strategic streamlining and reduced costs on certain projects, offset by increased trial costs

  • G&A EXPENSES - Decreased G&A expenses due to lower stock compensation and employee costs contributed to narrower net loss

Company press release: ID:nGNXnG1fm

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$7 mln

$4.97 mln (9 Analysts)

Q4 EPS

-$0.32

Q4 Net Income

Beat

-$54.89 mln

-$68.09 mln (7 Analysts)

Q4 Basic EPS

-$0.32

Q4 Operating Expenses

$67.63 mln

Q4 Operating Income

-$60.63 mln

Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy."

  • Wall Street's median 12-month price target for Relay Therapeutics Inc is $14.00, about 51.8% above its February 25 closing price of $9.22

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment